Want to see MLAB full AI Analyst Report?

Mesa Laboratories (MLAB) Revenue by Segment

93 Followers

Revenue by Segment

Sterilization & Disinfection Control has emerged as the clear growth engine, accelerating sharply and driving company momentum, while Calibration Solutions delivers steady, resilient baseline growth and Clinical Genomics shows modest recovery from prior weakness. By contrast, Biopharmaceutical Development just suffered a sudden, material quarterly drop after a period of recovery—flagging project/timing volatility or lost contracts that could swing near-term results. Investor takeaway: revenue concentration is shifting toward sterilization; confirm its sustainability and watch biopharma volatility as a near-term guidance risk.

Date	Sterilization & Disinfection Control	Biopharmaceutical Development	Calibration Solutions	Clinical Genomics
Mar 31, 2026	$29.14M	$8.85M	$13.56M	$12.18M
Dec 31, 2025	$24.91M	$14.37M	$14.07M	$11.77M
Sep 30, 2025	$22.11M	$13.92M	$13.57M	$11.14M
Jun 30, 2025	$25.41M	$11.49M	$12.35M	$10.30M
Mar 31, 2025	$24.75M	$12.62M	$13.26M	$11.51M
Dec 31, 2024	$23.51M	$12.24M	$14.43M	$12.67M
Sep 30, 2024	$22.20M	$11.87M	$12.26M	$11.50M
Jun 30, 2024	$22.96M	$12.01M	$11.80M	$11.40M
Mar 31, 2024	$22.78M	$12.19M	$12.81M	$11.12M
Dec 31, 2023	$19.34M	$9.43M	$12.16M	$12.55M